Reimagining Medicine
Company overview
Innovation: Pipeline overview
Cardiovascular
Ophthalmology
Financial review
Immunology
libvatrep - TRPV1 antagonist
NCT04630158 SAHARA (CSAF312B12201)
Chronic ocular surface pain
Phase 2
Indication
Phase
Patients
150
Primary
Outcome
Change in mean pain severity Visual Analog Scale
Measures
2023 priorities
Innovation: Clinical trials
Neuroscience
Global Health
Arms
Intervention
Target
Patients
Placebo Comparator: SAF312 Placebo. Randomized to a 1:1:1 topical eye
drops, twice daily
Experimental: SAF312 dose 1. Randomized to a 1:1:1 topical eye drops,
twice daily
Experimental: SAF312 dose 2. Randomized to a 1:1:1 topical eye drops,
twice daily
Subjects with CICP persisting at least for 4 months after refractive surgery and
chronicity confirmed during the observational period.
Readout
Milestone(s)
2023
Publication
2023
98 Investor Relations | Q4 2022 Results
Appendix
Abbreviations
Oncology
Other
Biosimilars
1 NOVARTIS | Reimagining MedicineView entire presentation